Benzodiazepines

First-line therapy for alcohol withdrawal, because they are the most effective agents at preventing complications such as seizures and delirium and at reducing withdrawal severity. The logic is cross-tolerance: benzodiazepines enhance GABA signaling, substituting for alcohol’s lost inhibitory push against the glutamate excess. Diazepam is a common first choice for its rapid onset and long duration, and chlordiazepoxide is a long-acting front-loading agent; when liver disease is a concern, lorazepam — with minimal hepatic metabolism — is used instead, and older adults need lower doses or longer intervals. Dose symptom-triggered to the withdrawal score, and expect aggressive dosing with close monitoring in severe withdrawal.

Anxiety and breathlessness near the end of life. "The use of opioids and benzodiazepines for breathlessness, glycopyrrolate for increased secretions, antipsychotics for delirium, and other non-pharmacological treatment options may be indicated in patients approaching their end of life."

❗ THE PTSD CARVE-OUT COMES FIRST, because it reverses everything that follows. VA/DoD 2023 recommends AGAINST benzodiazepines for the treatment of PTSD — a STRONG recommendation against (Rec 19) — and for acute stress disorder finds insufficient evidence to recommend for or against any pharmacotherapy (Rec 6). (The same guideline recommends against cannabis or cannabis derivatives for PTSD, Rec 20, Strong against.) So a benzodiazepine reached for in the hours or weeks after a trauma is not a gap in the plan being filled; it is a recommendation being crossed. Everything below applies to the ANXIETY disorders on this page, not to PTSD or ASD. Precisely positioned there: second-line for long-term use, first choice for immediate relief. The sourced wording is worth keeping intact — "benzodiazepines are prescribed for their immediate effect in relieving anxiety. For long-term use, benzodiazepines are considered a second-line treatment for anxiety, with antidepressants or buspirone considered first-line treatment, as well as an as-needed treatment for any distressing flare-ups of symptoms. These drugs are known for their rapid onset." The disorder-side rationale for the commonest real-world use is the bridging role: in panic disorder with severe symptoms or comorbidity, "it is preferred that a benzodiazepine such as alprazolam is used until the anti-depressants take effect" — the benzodiazepine covers the SSRI’s weeks-long onset lag, then comes off. Tolerance and dependence are the reason the course is short: "people can build up a tolerance if taken over a long period of time, and they may need higher and higher doses to get the same effect. Benzodiazepines are a Schedule IV controlled substance because they have a potential for misuse and can cause dependence," so they are "typically prescribed for short periods of time, especially for people who have a history of substance use disorders." Withdrawal is physiological and specific: "sleep disturbances, irritability, increased tension and anxiety, hand tremors, sweating, difficulty concentrating, nausea and vomiting, weight loss, palpitations, headache, muscular pain, and perceptual changes" — so "benzodiazepines should be tapered off slowly." The boxed warning covers three distinct hazards: concurrent use with opioids may result in profound sedation, respiratory depression, coma and death; use "exposes users to risks of misuse, substance use disorder, and addiction"; and "abrupt discontinuation or rapid dosage reduction may precipitate life-threatening withdrawal reactions." Children and older adults are more susceptible to sedation and respiratory depression and may have paradoxical reactions — tremors, agitation or visual hallucinations — and benzodiazepines may cause fetal harm in pregnancy. On overdose: central nervous system depression "ranging from drowsiness to coma," treated mainly supportively with airway protection, with flumazenil available but carrying a seizure risk, particularly in chronic users.

The other rapid-tranquilization class, and first-line for withdrawal and stimulant toxicity. "For clients with agitation from drug intoxication or withdrawal from an unknown cause, benzodiazepines are typically prescribed. Lorazepam and midazolam are used most often." "Benzodiazepines are the first-line therapy for agitated patients with alcohol withdrawal or central nervous system stimulant toxicity from cocaine or amphetamines." Monitor closely afterwards — they "may cause respiratory depression and excessive sedation." The chemical-restraint line: "administering prescribed benzodiazepines as standard treatment to manage the symptoms of a diagnosed mental health disorder is not considered a chemical restraint, but administering benzodiazepines to limit a client’s movement is considered a chemical restraint."

[Trigeminal neuralgia] Clonazepam is among second-line agents, though "comprehensive efficacy data is lacking."

Avoid — a precipitant. Benzodiazepines are on the StatPearls trigger list and "can potentially exacerbate encephalopathy and impede recovery"; the KASL work-up table says to stop the benzodiazepine. Lorazepam can itself cause asterixis. Flumazenil "is not a recommended treatment for hepatic encephalopathy."

No added benefit — "Diazepam and systemic steroids provide no additional benefit" in acute back pain with radiculopathy.

Caution. On StatPearls’ avoid list; "Use of sedatives and hypnotics" is a risk factor. If a sedative is used in hospital to help CPAP tolerance, "close monitoring is critical, as sedatives or anxiolytics can decrease consciousness and respiratory drive." NHS: do not take sleeping pills "unless recommended by a doctor – they can make sleep apnoea worse."

Three sourced disorder-side roles, all adjunctive and all short. Acute agitation: for "an agitated, potentially aggressive, acutely psychotic patient at risk of harming themselves or someone else," who should be hospitalized, "an injectable form of a typical antipsychotic with a benzodiazepine is most effective in this case." Short-term sedatives may also be considered for agitation or insomnia during a psychotic episode. Catatonia: benzodiazepines "have evidence as an effective treatment for catatonic symptoms of psychosis," and malignant catatonia specifically "shows robust responsiveness — reports reveal a full recovery in up to 80% of patients — with rapid initiation of benzodiazepines and electroconvulsive therapy." This is a genuinely high-stakes use: catatonia is "potentially fatal if untreated," and delayed diagnosis risks malnutrition, infection and death. NMS agitation: benzodiazepines "may be useful in controlling agitation" alongside stopping the offending agent and supportive care. A fourth, weaker role is akathisia, where benzodiazepines "have historically been used" although the supporting data are limited. The framing to teach: a benzodiazepine here calms the patient so the antipsychotic can work, or rescues a catatonic state — it never treats the psychosis itself.

The status-epilepticus first line (AES 2016, Level A), not chronic control: rapid GABA-A–mediated abortive therapy given at 5 minutes — IM midazolam 10 mg (> 40 kg) when there’s no IV, IV lorazepam 0.1 mg/kg (max 4 mg/dose, may repeat once), or IV diazepam 0.15–0.2 mg/kg (max 10 mg/dose). Adequately dosed, benzodiazepines stop ~60–70% of convulsive status — and underdosing is a frequent, avoidable cause of failure, because ongoing seizures internalize the very GABA-A receptors the drug needs.

Double-edged, and both edges are sourced. The positive role is first-line sedation in stimulant toxicity — for agitation, for seizure prevention, and as the intervention that lowers temperature, blood pressure and heart rate together. The second positive role is substitution in sedative withdrawal: "substituting the short-acting benzodiazepine the individual has been using with a long-acting one, such as diazepam or clonazepam, which provides more stable blood levels and reduces the intensity of withdrawal symptoms. The medication is then gradually tapered… The tapering process can last several weeks to several months." The negative role is a co-prescribing rule that exists because of a boxed warning: "use of benzodiazepines and zolpidem is NOT recommended for clients receiving methadone or buprenorphine therapy unless they are under close medical supervision due to the risk of oversedation." The same principle governs methadone generally — it "is medically safe, provided there is no concomitant use of other prescription or illicit drugs." And the withdrawal these drugs produce is the dangerous kind: tremor and rebound anxiety escalating through hallucinations and agitation to seizures within one to five days of abrupt cessation or rapid tapering, with autonomic instability. That is the sourced basis for the contrast this page teaches — GABAergic withdrawal, whether from alcohol or benzodiazepines, has documented seizure and delirium risk, and the Alcohol Withdrawal page carries the parallel picture in full.

Potent pain control via µ-opioid receptor agonism. Watch for respiratory depression; reverse with naloxone.

First-line antidepressants that raise synaptic serotonin. Delayed onset; watch for serotonin syndrome and early suicidality.

Stabilize neuronal firing to prevent seizures. Many are narrow-therapeutic-index — level monitoring and rash vigilance are essential.

A widely used fever/pain reliever with no anti-inflammatory or platelet effect — but hepatotoxic in overdose.

Dopamine-blocking drugs for psychosis. Watch EPS, NMS, metabolic effects — boxed warning in elderly dementia.

Lithium controls bipolar mania but has a tiny therapeutic window — levels are everything.